Nasdaq · Common Stock · Surgical & Medical Instruments & Apparatus
21 entities across 16 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-26 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| LeMaitre Vascular GmbH | Germany | |
| LeMaitre Vascular GK | Japan | |
| LeMaitre Acquisition LLC | Delaware | |
| LeMaitre Vascular SAS | France | |
| LeMaitre Vascular Spain, S.L. | Spain | |
| LeMaitre Vascular S.r.l. | Italy | |
| Vascutech Acquisition LLC | Delaware | |
| LeMaitre Vascular ULC | Canada | |
| LeMaitre Vascular Switzerland GmbH | Switzerland | |
| LeMaitre Vascular AS | Norway | |
| LeMaitre Vascular Pty Ltd | Australia | |
| LeMaitre Medical Technology (Shanghai) Co., Ltd | China | |
| LeMaitre Vascular, Ltd | United Kingdom | |
| Bio Nova Holdings Pty Ltd | Australia | |
| Bio Nova International Pty Ltd | Australia | |
| LeMaitre Cardial SAS | France | |
| LeMaitre Pte Ltd | Singapore | |
| LeMaitre Ltd | Korea | |
| LeMaitre Co., Ltd | Thailand | |
| LeMaitre Ireland Ltd | Ireland | |
| LeMaitre Acquisition Pty Ltd | Australia |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $129.4M | $21.2M | $31.8M | 65.4% | 20,479,000 |
| FY2021 | $154.4M | $26.9M | $30.2M | 65.7% | 21,475,000 |
| FY2022 | $161.7M | $20.6M | $22.1M | 64.9% | 22,171,000 |
| FY2023 | $193.5M | $30.1M | $29.5M | 65.7% | 22,423,000 |
| FY2024 | $219.9M | $44.0M | $37.2M | 68.6% | 22,779,000 |
| FY2025 | $249.6M | $57.7M | $74.5M | 71.5% | 22,929,000 |
11 institutions tracked — 6 added, 5 reduced.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 755,142 | +460,148 | $72.5M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 788,835 | +130,390 | $75.7M |
| BlackRock, Inc. | Index | 3,272,973 | +128,822 | $314.1M |
| MORGAN STANLEY | Active fund | 351,083 | −56,688 | $33.7M |
| CITADEL ADVISORS LLC | Hedge fund | 48,833 | −54,550 | $4.7M |
| STATE STREET CORP | Index | 901,416 | +45,632 | $86.5M |
| JPMORGAN CHASE & CO | Active fund | 68,946 | −39,239 | $6.7M |
| BANK OF AMERICA CORP /DE/ | Active fund | 140,936 | −39,159 | $13.5M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 169,502 | +31,000 | $16.3M |
| FMR LLC | Active fund | 6,444 | −619 | $618,363 |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 20,623 | +221 | $2.0M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
LEMAITRE VASCULAR INC files under SIC 3841 — all 38 surgical & medical instruments & apparatus companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
